The Discounted Cash Flow (DCF) valuation of Biomarin Pharmaceutical Inc (BMRN) is 48.64 USD. With the latest stock price at 53.57 USD, the upside of Biomarin Pharmaceutical Inc based on DCF is -9.2%.
Based on the latest price of 53.57 USD and our DCF valuation, Biomarin Pharmaceutical Inc (BMRN) is a sell. selling Biomarin stocks now will result in a potential gain of 9.2%.
| Range | Selected | |
| WACC / Discount Rate | 8.2% - 11.2% | 9.7% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 35.79 - 80.93 | 48.64 |
| Upside | -33.2% - 51.1% | -9.2% |